1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD30 is a potential therapeutic target in patients with HTLV-1 associated adult T-cell leukemia/lymphoma presenting outside of Japan
    Meeting Abstract

    Lunning, M. A.; Chiu, A.; Feldstein, J. T.; Maragulia, J. C.; Moskowitz, A.; Matasar, M. J.; Straus, D. J.; Noy, A.; Myskowski, P. L.; Zelenetz, A. D.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Prioritizing content in continuing hematologic oncology education: A survey of 51 clinical investigators
    Meeting Abstract

    Love, N.; Horwitz, S. M.; Lonial, S.; Palumbo, A.; Smith, M. R.; Hussein, A. M.; Ziel, K.
    Blood (2012)

    Fulltext@MSK | Save
  • Clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides: A single center experience from Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Li, J. Y.; Pulitzer, M.; Myskowski, P. L.; Dusza, S.; Horwitz, S. M.; Moskowitz, A.; Querfeld, C.
    Blood (2012)

    Fulltext@MSK | Save
  • Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression
    Meeting Abstract

    Krathen, M.; Sundram, U.; Bashey, S.; Sutherland, K.; Salva, K.; Wood, G. S.; Advani, R. H.; Hoppe, R. T.; Reddy, S.; Armstrong, R.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: Interim results
    Meeting Abstract

    Jacobsen, E. D.; Advani, R. H.; Oki, Y.; Sharman, J.; Horwitz, S. M.; Forero-Torres, A.; O'Connor, O. A.; Shustov, A. R.; Siddiqi, T.; Grove, L. E.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Biomarker quality assurance (QA) findings from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry
    Meeting Abstract

    Hsi, E. D.; Gruver, A. M.; Foss, F. M.; Carson, K. R.; Pinter-Brown, L.; Horwitz, S. M.; Rosen, S. T.; Pro, B.; Federico, M.; Gisselbrecht, C.
    Blood (2012)

    Fulltext@MSK | Save
  • Comparison of referring and final pathology for T-cell lymphomas in the NCCN
    Meeting Abstract

    Herrera, A. F.; Crosby-Thompson, A.; Friedberg, J. W.; Abel, G. A.; Czuczman, M. S.; Gordon, L. I.; Kaminski, M. S.; Millenson, M.; Nademanee, A.; Niland, J.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): First detailed report of primary treatment
    Meeting Abstract

    Foss, F. M.; Carson, K. R.; Pinter-Brown, L.; Horwitz, S. M.; Rosen, S. T.; Pro, B.; Federico, M.; Gisselbrecht, C.; Hsi, E. D.
    Blood (2012)

    Fulltext@MSK | Save
  • Clinical safety and activity in a phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-Kinase-δ,γ, in patients with advanced hematologic malignancies
    Meeting Abstract

    Flinn, I. W.; Horwitz, S. M.; Patel, M.; Younes, A.; Porter, J. R.; Sweeney, J.; Allen, K.; Kelly, P.; Kahl, B. S.
    Blood (2012)

    Fulltext@MSK | Save
  • Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD3O-positive mature T-cell and NK-cell lymphomas
    Meeting Abstract

    Fanale, M. A.; Shustov, A. R.; Forero-Torres, A.; Bartlett, N. L.; Advani, R. H.; Pro, B.; Chen, R. W.; Davies, A.; Midge, T.; Kennedy, D. A.; more...
    Blood (2012)

    Fulltext@MSK | Save